Ishihara, Hisamitsu
Yamaguchi, Susumu
Nakao, Ikko
Asahina, Seitaro
Sakatani, Taishi
Funding for this research was provided by:
Astellas Pharma
Article History
Received: 30 November 2017
Accepted: 10 June 2018
First Online: 16 July 2018
Compliance with ethical standards
:
: HI has served on the scientific advisory board of Astellas Pharma Inc.; received lecture or consulting fees from Astellas Pharma Inc., MSD, Sanofi, Mitsubishi Tanabe Pharma, Boehringer Ingelheim Japan, and Novartis Pharma; and received grants/research support from Astellas Pharma Inc., Ono Pharmaceutical, Boehringer Ingelheim Japan, AstraZeneca, Sanofi, Mitsubishi Tanabe Pharma, Eli Lilly Japan, Daiichi-Sankyo, Novo Nordisk Pharma, Kyowa Hakko Kirin, and MSD. SY, IN, SA, and TS are employees of Astellas Pharma Inc., Japan.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: Informed consent or substitute for it was obtained from all patients for being included in the study. The study was approved by the institutional review board at each participating site.